Accounting for climate change by Kaplan, RS, Ramanna, K

Managing risks: a new framework by Kaplan, RS, Mikes, A

Downstream emissions disclosure: who and what? by Kaplan, RS, Ramanna, K

Accounting for carbon offsets: establishing the foundation for carbon-trading markets by Kaplan, RS, Ramanna, K, Roston, M

The risks you can’t foresee: what to do when there’s no playbook by Kaplan, RS, Leonard, HBD, Mikes, A

When every employee is a risk manager by Meyer, K, Mikes, A, Kaplan, RS

Mind the gap? The platform trial as a working environment by Morrell, L, Hordern, J, Brown, L, Sydes, MR, Amos, CL, Kaplan, RS, Parmar, MKB, Maughan, TS

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab by Madi, A, Fisher, D, Maughan, TS, Colley, JP, Meade, AM, Tejpar, S, Van Den Bosch, B, Maynard, J, Humphreys, V, Wasan, H, Adams, RA, Idziaszczyk, S, Harris, R, Kaplan, RS, Cheadle, JP

This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols by Schiavone, F, Bathia, R, Letchemanan, K, Masters, L, Amos, C, Bara, A, Brown, L, Gilson, C, Pugh, C, Atako, N, Hudson, F, Parmar, M, Langley, R, Kaplan, RS, Parker, C, Attard, G, Clarke, NW, Gillessen, S, James, ND, Maughan, T, Sydes, MR, The Stampede And Focus4 Trial Management Group

In-depth clinical and biological exploration of DNA damage immune response as a biomarker for oxaliplatin use in colorectal cancer by Malla, SB, Fisher, DJ, Domingo, E, Blake, A, Hassanieh, S, Redmond, KL, Richman, SD, Youdell, M, Walker, SM, Logan, GE, Chatzipli, A, Amirkhah, R, Humphries, MP, Craig, SG, McDermott, U, Seymour, MT, Morton, DG, Quirke, P, West, NP, Salto-Tellez, M, Kennedy, RD, Johnston, PG, Tomlinson, I, Koelzer, VH, Campo, L, Kaplan, RS, Longley, DB, Lawler, M, Maughan, TS, Brown, LC, Dunne, PD